Martin Reincke

List of Publications by Year
in descending order

169 papers	11,816 citations	29994 54 h-index	31759 101 g-index
172 all docs	172 docs citations	172 times ranked	6244 citing authors

#	Article	IF	Citations
1	Drug-resistant hypertension in primary aldosteronism patients undergoing adrenal vein sampling: the AVIS-2-RH study. European Journal of Preventive Cardiology, 2022, 29, e85-e93.	0.8	19
2	Endocrine risk factors for COVID-19: Endogenous and exogenous glucocorticoid excess. Reviews in Endocrine and Metabolic Disorders, 2022, 23, 233-250.	2.6	13
3	Plasma Steroid Profiling in Patients With Adrenal Incidentaloma. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e1181-e1192.	1.8	19
4	Pathophysiology and histopathology of primary aldosteronism. Trends in Endocrinology and Metabolism, 2022, 33, 36-49.	3.1	14
5	Medullary thyroid cancer with ectopic Cushing's syndrome: A multicentre case series. Clinical Endocrinology, 2022, 96, 847-856.	1.2	7
6	Feasibility of Imaging-Guided Adrenalectomy in Young Patients With Primary Aldosteronism. Hypertension, 2022, 79, 187-195.	1.3	13
7	Improving Diagnostic Efficiency with Frequency Double-Trees and Frequency Nets in Bayesian Reasoning. MDM Policy and Practice, 2022, 7, 238146832210866.	0.5	2
8	Personalized drug testing in human pheochromocytoma/paraganglioma primary cultures. Endocrine-Related Cancer, 2022, 29, 285-306.	1.6	12
9	Longâ€term morbidity and mortality in patients with Cushing's syndrome. Journal of Neuroendocrinology, 2022, 34, e13113.	1.2	31
10	Clinical Biology of the Pituitary Adenoma. Endocrine Reviews, 2022, 43, 1003-1037.	8.9	81
11	True unilateral primary aldosteronism exists, and unilateral adrenalectomy saves lives.. European Journal of Endocrinology, 2022, , .	1.9	2
12	The Saline Infusion Test for Primary Aldosteronism: Implications of Immunoassay Inaccuracy. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e2027-e2036.	1.8	27
13	Identification of predictive criteria for pathogenic variants of primary bilateral macronodular adrenal hyperplasia (PBMAH) gene ARMC5 in 352 unselected patients. European Journal of Endocrinology, 2022, 187, 123-134.	1.9	18
14	The NETting of pituitary adenoma: a gland illusion. Pituitary, 2022, 25, 349-351.	1.6	12
15	Improved pasireotide response in USP8 mutant corticotroph tumours in vitro. Endocrine-Related Cancer, 2022, 29, 503-511.	1.6	11
16	Whom Should We Screen for Cushing Syndrome? The Endocrine Society Practice Guideline Recommendations 2008 Revisited. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e3723-e3730.	1.8	14
17	The metabolic phenotype of patients with primary aldosteronism: impact of subtype and sex â€“ a multicenter-study of 3566 Caucasian and Asian subjects. European Journal of Endocrinology, 2022, 187, 361-372.	1.9	9
18	Histopathology and Genetic Causes of Primary Aldosteronism in Young Adults. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 2473-2482.	1.8	4

#	Article	IF	Citations
19	International Histopathology Consensus for Unilateral Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 42-54.	1.8	127
20	Adrenal Venous Samplingâ€“Guided Adrenalectomy Rates in Primary Aldosteronism: Results of an International Cohort (AVSTAT). Journal of Clinical Endocrinology and Metabolism, 2021, 106, e1400-e1407.	1.8	25
21	Volumetric Modeling of Adrenal Gland Size in Primary Bilateral Macronodular Adrenocortical Hyperplasia. Journal of the Endocrine Society, 2021, 5, bvaa162.	0.1	7
22	Single-cell molecular profiling of all three components of the HPA axis reveals adrenal ABCB1 as a regulator of stress adaptation. Science Advances, 2021, 7, .	4.7	42
23	Pituitary Neoplasm Nomenclature Workshop: Does Adenoma Stand the Test of Time?. Journal of the Endocrine Society, 2021, 5, bvaa205.	0.1	31
24	Circulating microRNA Expression in Cushingâ€™s Syndrome. Frontiers in Endocrinology, 2021, 12, 620012.	1.5	11
25	Genomics in Cushingâ€™s Disease: The Dawn of a New Era. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e2455-e2456.	1.8	7
26	Autonomous Cortisol Secretion Influences Psychopathological Symptoms in Patients With Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e2423-e2433.	1.8	7
27	Perspectives of the European Society of Endocrinology (ESE) and the European Society of Paediatric Endocrinology (ESPE) on rare endocrine disease. Endocrine, 2021, 71, 539-541.	1.1	3
28	Approach to the Patient Treated with Steroidogenesis Inhibitors. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 2114-2123.	1.8	39
29	Altered Taste Perception for Sodium Chloride in Patients With Primary Aldosteronism. Hypertension, 2021, 77, 1332-1340.	1.3	14
30	Characteristics of preoperative steroid profiles and glucose metabolism in patients with primary aldosteronism developing adrenal insufficiency after adrenalectomy. Scientific Reports, 2021, 11, 11181.	1.6	6
31	BEX1 Is Differentially Expressed in Aldosterone-Producing Adenomas and Protects Human Adrenocortical Cells From Ferroptosis. Hypertension, 2021, 77, 1647-1658.	1.3	8
32	Patients with low IGF-I after curative surgery for Cushingâ€™s syndrome have an adverse long-term outcome of hypercortisolism-induced myopathy. European Journal of Endocrinology, 2021, 184, 813-821.	1.9	13
33	The role of regulated necrosis in endocrine diseases. Nature Reviews Endocrinology, 2021, 17, 497-510.	4.3	35
34	Cushing Syndrome Associated Myopathy: It Is Time for a Change. Endocrinology and Metabolism, 2021, 36, 564-571.	1.3	16
35	Primary Aldosteronism: Metabolic Reprogramming and the Pathogenesis of Aldosterone-Producing Adenomas. Cancers, 2021, 13, 3716.	1.7	6
36	Identification of Surgically Curable Primary Aldosteronism by Imaging in a Large, Multiethnic International Study. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e4340-e4349.	1.8	18

#	Article	IF	Citations
37	Single-Center Prospective Cohort Study on the Histopathology, Genotype, and Postsurgical Outcomes of Patients With Primary Aldosteronism. Hypertension, 2021, 78, 738-746.	1.3	35
38	Targeted Metabolomics as a Tool in Discriminating Endocrine From Primary Hypertension. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e1111-e1128.	1.8	19
39	IGF-I/IGFBP3/ALS Deficiency in Sarcopenia: Low GHBP Suggests GH Resistance in a Subgroup of Geriatric Patients. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 1698-1707.	1.8	13
40	Development of a Prediction Score to Avoid Confirmatory Testing in Patients With Suspected Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 1708-1716.	1.8	16
41	Consensus on diagnosis and management of Cushing's disease: a guideline update. Lancet Diabetes and Endocrinology,the, 2021, 9, 847-875.	5.5	315
42	Metformin and Bone Metabolism in Endogenous Glucocorticoid Excess: An Exploratory Study. Frontiers in Endocrinology, 2021, 12, 765067.	1.5	5
43	Genomic epidemiology reveals multiple introductions of SARS-CoV-2 followed by community and nosocomial spread, Germany, February to May 2020. Eurosurveillance, 2021, 26, .	3.9	11
44	Diagnosis and treatment of primary aldosteronism. Lancet Diabetes and Endocrinology,the, 2021, 9, 876-892.	5.5	106
45	Evidence for increased SARS-CoV-2 susceptibility and COVID-19 severity related to pre-existing immunity to seasonal coronaviruses. Cell Reports, 2021, 37, 110169.	2.9	34
46	Subtyping of Primary Aldosteronism in the AVIS-2 Study: Assessment of Selectivity and Lateralization. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 2042-2052.	1.8	65
47	Glucocorticoid Receptor Polymorphisms Influence Muscle Strength in Cushingâ€™s Syndrome. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 305-313.	1.8	14
48	Patients With Primary Aldosteronism Respond to Unilateral Adrenalectomy With Long-Term Reduction in Salt Intake. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e484-e493.	1.8	12
49	Response to the Letter to the Editor: â€œLong-Term Outcome of Primary Bilateral Macronodular Adrenocortical Hyperplasia After Unilateral Adrenalectomyâ€• Journal of Clinical Endocrinology and Metabolism, 2020, 105, e922-e923.	1.8	0
50	Response to Letter to the Editor: â€œImpaired Glucose Metabolism in Primary Aldosteronism Is Associated with Cortisol Cosecretionâ€• Journal of Clinical Endocrinology and Metabolism, 2020, 105, e916-e917.	1.8	1
51	Time to Diagnosis in Cushingâ€™s Syndrome: A Meta-Analysis Based on 5367 Patients. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e12-e22.	1.8	69
52	The Primary Aldosteronism Surgical Outcome Score for the Prediction of Clinical Outcomes After Adrenalectomy for Unilateral Primary Aldosteronism. Annals of Surgery, 2020, 272, 1125-1132.	2.1	66
53	Histological Characterization of Aldosterone-producing Adrenocortical Adenomas with Different Somatic Mutations. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e282-e289.	1.8	29
54	Use of Steroid Profiling Combined With Machine Learning for Identification and Subtype Classification in Primary Aldosteronism. JAMA Network Open, 2020, 3, e2016209.	2.8	53

#	Article	IF	Citations
55	Urine steroid metabolomics for the differential diagnosis of adrenal incidentalomas in the EURINE-ACT study: a prospective test validation study. Lancet Diabetes and Endocrinology,the, 2020, 8, 773-781.	5.5	129
56	Recurrence after pituitary surgery in adult Cushingâ€™s disease: a systematic review on diagnosis and treatment. Endocrine, 2020, 70, 218-231.	1.1	40
57	The potential pathophysiological role of aldosterone and the mineralocorticoid receptor in anxiety and depression â€“ Lessons from primary aldosteronism. Journal of Psychiatric Research, 2020, 130, 82-88.	1.5	20
58	Subtype diagnosis, treatment, complications and outcomes of primary aldosteronism and future direction of research: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension â^—. Journal of Hypertension, 2020, 38, 1929-1936.	0.3	74
59	Systemic Effects by Intrathecal Administration of Triamcinolone Acetonide in Patients With Multiple Sclerosis. Frontiers in Endocrinology, 2020, 11, 574.	1.5	4
60	Persisting Muscle Dysfunction in Cushingâ€™s Syndrome Despite Biochemical Remission. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e4490-e4498.	1.8	29
61	Nomogram-Based Preoperative Score for Predicting Clinical Outcome in Unilateral Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e4382-e4392.	1.8	20
62	The Impact of Glucocorticoid Co-Secretion in Primary Aldosteronism on Thyroid Autoantibody Titers During the Course of Disease. Hormone and Metabolic Research, 2020, 52, 404-411.	0.7	6
63	Development and Validation of Prediction Models for Subtype Diagnosis of Patients With Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3706-e3717.	1.8	47
64	Spironolactone reduces biochemical markers of bone turnover in postmenopausal women with primary aldosteronism. Endocrine, 2020, 69, 625-633.	1.1	10
65	Glucocorticoid Excess in Patients with Pheochromocytoma Compared with Paraganglioma and Other Forms of Hypertension. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3374-e3383.	1.8	17
66	Metformin: the white knight fighting corticosteroid side-effects. Lancet Diabetes and Endocrinology,the, 2020, 8, 258-259.	5.5	2
67	Mass Spectrometry Imaging Establishes 2 Distinct Metabolic Phenotypes of Aldosterone-Producing Cell Clusters in Primary Aldosteronism. Hypertension, 2020, 75, 634-644.	1.3	33
68	What is the role of medical therapy in adrenal-dependent Cushing's syndrome?. Best Practice and Research in Clinical Endocrinology and Metabolism, 2020, 34, 101376.	2.2	7
69	Mass spectrometry reveals misdiagnosis of primary aldosteronism with scheduling for adrenalectomy due to immunoassay interference. Clinica Chimica Acta, 2020, 507, 98-103.	0.5	8
70	ENDOCRINOLOGY IN THE TIME OF COVID-19: Management of Cushing's syndrome. European Journal of Endocrinology, 2020, 183, G1-G7.	1.9	61
71	Mass spectrometry-based steroid profiling in primary bilateral macronodular adrenocortical hyperplasia. Endocrine-Related Cancer, 2020, 27, 403-413.	1.6	13
72	Prospective evaluation of aldosterone LC-MS/MS-specific cutoffs for the saline infusion test. European Journal of Endocrinology, 2020, 183, 191-201.	1.9	8

#	Article	IF	Citations
73	Fibroblast Growth Factor 23-Producing Phosphaturic Mesenchymal Tumor with Extraordinary Morphology Causing Oncogenic Osteomalacia. Medicina (Lithuania), 2020, 56, 34.	0.8	4
74	Treatment of Unilateral PA by Adrenalectomy: Potential Reasons for Incomplete Biochemical Cure. Experimental and Clinical Endocrinology and Diabetes, 2019, 127, 100-108.	0.6	15
75	Driver mutations in USP8 wild-type Cushingâ€™s disease. Neuro-Oncology, 2019, 21, 1273-1283.	0.6	65
76	Adrenal Insufficiency After Unilateral Adrenalectomy in Primary Aldosteronism: Long-Term Outcome and Clinical Impact. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 5658-5664.	1.8	37
77	Synergistic Highly Potent Targeted Drug Combinations in Different Pheochromocytoma Models Including Human Tumor Cultures. Endocrinology, 2019, 160, 2600-2617.	1.4	24
78	Plasma Steroid Profiles in Subclinical Compared With Overt Adrenal Cushing Syndrome. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 4331-4340.	1.8	35
79	Clinical Outcomes of 1625 Patients With Primary Aldosteronism Subtyped With Adrenal Vein Sampling. Hypertension, 2019, 74, 800-808.	1.3	97
80	Steroid Profiling and Immunohistochemistry for Subtyping and Outcome Prediction in Primary Aldosteronismâ€”a Review. Current Hypertension Reports, 2019, 21, 77.	1.5	17
81	Primary Aldosteronism. Hypertension, 2019, 74, 809-816.	1.3	27
82	Treatment of Primary Aldosteronism With mTORC1 Inhibitors. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 4703-4714.	1.8	7
83	Primary aldosteronism long-term outcome: Medical versus surgical therapy. Current Opinion in Endocrine and Metabolic Research, 2019, 8, 132-138.	0.6	4
84	Therapeutic options after surgical failure in Cushing's disease: A critical review. Best Practice and Research in Clinical Endocrinology and Metabolism, 2019, 33, 101270.	2.2	20
85	Impaired Glucose Metabolism in Primary Aldosteronism Is Associated With Cortisol Cosecretion. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 3192-3202.	1.8	72
86	Long-Term Outcome of Primary Bilateral Macronodular Adrenocortical Hyperplasia After Unilateral Adrenalectomy. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 2985-2993.	1.8	49
87	Tumor-Directed Therapeutic Targets in Cushing Disease. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 925-933.	1.8	24
88	Circulating miRNA Expression Profiling in Primary Aldosteronism. Frontiers in Endocrinology, 2019, 10, 739.	1.5	21
89	Toward a Diagnostic Score in Cushing's Syndrome. Frontiers in Endocrinology, 2019, 10, 766.	1.5	46
90	Sarcopenia â€“ Endocrinological and Neurological Aspects. Experimental and Clinical Endocrinology and Diabetes, 2019, 6, 8-22.	0.6	23

#	Article	IF	Citations
91	Proteomic Landscape of Aldosterone-Producing Adenoma. Hypertension, 2019, 73, 469-480.	1.3	19
92	Classification of microadenomas in patients with primary aldosteronism by steroid profiling. Journal of Steroid Biochemistry and Molecular Biology, 2019, 189, 274-282.	1.2	28
93	In situ metabolomics of aldosterone-producing adenomas. JCI Insight, 2019, 4, .	2.3	27
94	Safety of medical adjustment and confirmatory testing in the diagnostic work-up of primary aldosteronism. European Journal of Endocrinology, 2019, 181, 421-428.	1.9	11
95	Metabolic impact of pheochromocytoma/paraganglioma: targeted metabolomics in patients before and after tumor removal. European Journal of Endocrinology, 2019, 181, 647-657.	1.9	19
96	Timeline of Advances in Genetics of Primary Aldosteronism. Experientia Supplementum (2012), 2019, 111, 213-243.	0.5	3
97	MANAGEMENT OF ENDOCRINE DISEASE: Diagnosis and management of primary aldosteronism: the Endocrine Society guideline 2016 revisited. European Journal of Endocrinology, 2018, 179, R19-R29.	1.9	89
98	Worse Healthâ€Related Quality of Life at longâ€term followâ€up in patients with Cushing's disease than patients with cortisol producing adenoma. Data from the <scp>ERCUSYN</scp>. Clinical Endocrinology, 2018, 88, 787-798.	1.2	40
99	Primary aldosteronism: key characteristics at diagnosis: a trend toward milder forms. European Journal of Endocrinology, 2018, 178, 605-611.	1.9	26
100	Anxiety, Depression, and Impaired Quality of Life in Primary Aldosteronism: Why We Shouldnâ€™t Ignore It!. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 1-4.	1.8	39
101	Targeting CXCR4 (CXC Chemokine Receptor Type 4) for Molecular Imaging of Aldosterone-Producing Adenoma. Hypertension, 2018, 71, 317-325.	1.3	77
102	Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016. European Journal of Endocrinology, 2018, 178, 265-276.	1.9	196
103	Advanced neuroendocrine tumours of the small intestine and pancreas: clinical developments, controversies, and future strategies. Lancet Diabetes and Endocrinology,the, 2018, 6, 404-415.	5.5	56
104	Adrenal Surgery for Cushingâ€™s Syndrome. Endocrinology and Metabolism Clinics of North America, 2018, 47, 385-394.	1.2	19
105	Genetics of Cushing's disease. Clinical Endocrinology, 2018, 88, 3-12.	1.2	27
106	DIAGNOSIS OF ENDOCRINE DISEASE: 18-Oxocortisol and 18-hydroxycortisol: is there clinical utility of these steroids?. European Journal of Endocrinology, 2018, 178, R1-R9.	1.9	39
107	Plasma Steroid Metabolome Profiling for Diagnosis and Subtyping Patients with Cushing Syndrome. Clinical Chemistry, 2018, 64, 586-596.	1.5	70
108	Cortisol Excess in Patients With Primary Aldosteronism Impacts Left Ventricular Hypertrophy. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 4543-4552.	1.8	47

#	Article	IF	Citations
109	The <scp>USP</scp>8 mutational status may predict longâ€term remission in patients with Cushing's disease. Clinical Endocrinology, 2018, 89, 454-458.	1.2	56
110	Immunohistopathology and Steroid Profiles Associated With Biochemical Outcomes After Adrenalectomy for Unilateral Primary Aldosteronism. Hypertension, 2018, 72, 650-657.	1.3	51
111	Computed Tomography and Adrenal Venous Sampling in the Diagnosis of Unilateral Primary Aldosteronism. Hypertension, 2018, 72, 641-649.	1.3	94
112	Pathogenesis of Cushing Disease: An Update on the Genetics of Corticotropinomas. Endocrine Practice, 2018, 24, 907-914.	1.1	13
113	Somatic USP8 mutations are frequent events in corticotroph tumor progression causing Nelsonâ€™s tumor. European Journal of Endocrinology, 2018, 178, 57-63.	1.9	37
114	Reference intervals for plasma concentrations of adrenal steroids measured by LC-MS/MS: Impact of gender, age, oral contraceptives, body mass index and blood pressure status. Clinica Chimica Acta, 2017, 470, 115-124.	0.5	116
115	Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes and Endocrinology,the, 2017, 5, 689-699.	5.5	595
116	Cortisol-related metabolic alterations assessed by mass spectrometry assay in patients with Cushing's syndrome. European Journal of Endocrinology, 2017, 177, 227-237.	1.9	23
117	Persistence of myopathy in Cushingâ€™s syndrome: evaluation of the German Cushingâ€™s Registry. European Journal of Endocrinology, 2017, 176, 737-746.	1.9	57
118	Diagnostic tests for Cushing's syndrome differ from published guidelines: data from ERCUSYN. European Journal of Endocrinology, 2017, 176, 613-624.	1.9	42
119	Old and New Concepts in the Molecular Pathogenesis of Primary Aldosteronism. Hypertension, 2017, 70, 875-881.	1.3	35
120	Expression and mutational status of USP8 in tumors causing ectopic ACTH secretion syndrome. Endocrine-Related Cancer, 2017, 24, L73-L77.	1.6	14
121	Cushingâ€™s syndrome: a model for sarcopenic obesity. Endocrine, 2017, 57, 481-485.	1.1	26
122	Disordered CYP11B2 Expression in Primary Aldosteronism. Hormone and Metabolic Research, 2017, 49, 957-962.	0.7	31
123	The impact of Connshing's syndrome - mild cortisol excess in primary aldosteronism drives diabetes risk. Journal of Hypertension, 2017, 35, 2548.	0.3	18
124	Steroid metabolome analysis reveals prevalent glucocorticoid excess in primary aldosteronism. JCI Insight, 2017, 2, .	2.3	187
125	Genetic Landscape of Sporadic Unilateral Adrenocortical Adenomas Without PRKACA p.Leu206Arg Mutation. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 3526-3538.	1.8	65
126	PRKACA Somatic Mutations Are Rare Findings in Aldosterone-Producing Adenomas. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 3010-3017.	1.8	43

#	Article	IF	Citations
127	Mass Spectrometryâ€“Based Adrenal and Peripheral Venous Steroid Profiling for Subtyping Primary Aldosteronism. Clinical Chemistry, 2016, 62, 514-524.	1.5	123
128	Genotype-Specific Steroid Profiles Associated With Aldosterone-Producing Adenomas. Hypertension, 2016, 67, 139-145.	1.3	127
129	The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 1889-1916.	1.8	1,921
130	Landscape of somatic mutations in sporadic GH-secreting pituitary adenomas. European Journal of Endocrinology, 2016, 174, 363-372.	1.9	100
131	Clinical Management and Outcomes of Adrenal Hemorrhage Following Adrenal Vein Sampling in Primary Aldosteronism. Hypertension, 2016, 67, 146-152.	1.3	63
132	Increased prevalence of diabetes mellitus and the metabolic syndrome in patients with primary aldosteronism of the German Conn's Registry. European Journal of Endocrinology, 2015, 173, 665-675.	1.9	115
133	Cost-Effectiveness of Screening for Primary Aldosteronism and Subtype Diagnosis in the Resistant Hypertensive Patients. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, 621-630.	0.9	45
134	Genetic and Potential Autoimmune Triggers of Primary Aldosteronism. Hypertension, 2015, 66, 248-253.	1.3	10
135	Time to Recovery of Adrenal Function After Curative Surgery for Cushing's Syndrome Depends on Etiology. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 1300-1308.	1.8	65
136	THERAPY OF ENDOCRINE DISEASE: Outcomes in patients with Cushing's disease undergoing transsphenoidal surgery: systematic review assessing criteria used to define remission and recurrence. European Journal of Endocrinology, 2015, 172, R227-R239.	1.9	114
137	Post-saline infusion test aldosterone levels indicate severity and outcome in primary aldosteronism. European Journal of Endocrinology, 2015, 172, 443-450.	1.9	26
138	The Gene of the Ubiquitin-Specific Protease 8 Is Frequently Mutated in Adenomas Causing Cushing's Disease. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E997-E1004.	1.8	163
139	Decoding the genetic basis of Cushing's disease: USP8 in the spotlight. European Journal of Endocrinology, 2015, 173, M73-M83.	1.9	46
140	Subclinical hypercortisolism: a state, a syndrome, or a disease?. European Journal of Endocrinology, 2015, 173, M61-M71.	1.9	104
141	Coexisting Prolactinoma and Primary Aldosteronism: Is There a Pathophysiological Link?. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E1262-E1269.	1.8	4
142	A critical reappraisal of bilateral adrenalectomy for ACTH-dependent Cushing's syndrome. European Journal of Endocrinology, 2015, 173, M23-M32.	1.9	74
143	Mutations in the deubiquitinase gene USP8 cause Cushing's disease. Nature Genetics, 2015, 47, 31-38.	9.4	450
144	Adrenal vein sampling in primary aldosteronism: towards a standardised protocol. Lancet Diabetes and Endocrinology,the, 2015, 3, 296-303.	5.5	134

#	Article	IF	Citations
145	Genetic Spectrum and Clinical Correlates of Somatic Mutations in Aldosterone-Producing Adenoma. Hypertension, 2014, 64, 354-361.	1.3	248
146	Age Below 40 or a Recently Proposed Clinical Prediction Score Cannot Bypass Adrenal Venous Sampling in Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E1035-E1039.	1.8	95
147	Gender differences in anxiety and depressive symptoms in patients with primary hyperaldosteronism: A cross-sectional study. World Journal of Biological Psychiatry, 2014, 15, 26-35.	1.3	62
148	Outcome of Adrenal Vein Sampling Performed During Concurrent Mineralocorticoid Receptor Antagonist Therapy. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 4397-4402.	1.8	58
149	Favorable long-term outcomes of bilateral adrenalectomy in Cushing's disease. European Journal of Endocrinology, 2014, 171, 209-215.	1.9	83
150	Somatic ATP1A1 , ATP2B3 , and KCNJ5 Mutations in Aldosterone-Producing Adenomas. Hypertension, 2014, 63, 188-195.	1.3	151
151	Linear and Volumetric Evaluation of the Adrenal Glandâ€"MDCT-Based Measurements of the Adrenals. Academic Radiology, 2014, 21, 1465-1474.	1.3	41
152	Adrenal Function After Adrenalectomy for Subclinical Hypercortisolism and Cushing's Syndrome: A Systematic Review of the Literature. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 2637-2645.	1.8	99
153	Outcome of Bilateral Adrenalectomy in Cushing's Syndrome: A Systematic Review. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 3939-3948.	1.8	163
154	Somatic mutations in ATP1A1 and ATP2B3 lead to aldosterone-producing adenomas and secondary hypertension. Nature Genetics, 2013, 45, 440-444.	9.4	460
155	Lack of influence of somatic mutations on steroid gradients during adrenal vein sampling in aldosterone-producing adenoma patients. European Journal of Endocrinology, 2013, 169, 657-663.	1.9	22
156	Aldosterone Excess Impairs First Phase Insulin Secretion in Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 2513-2520.	1.8	80
157	Effectiveness of eplerenone or spironolactone treatment in preserving renal function in primary aldosteronism. European Journal of Endocrinology, 2013, 168, 75-81.	1.9	58
158	Frequency and causes of adrenal crises over lifetime in patients with 21-hydroxylase deficiency. European Journal of Endocrinology, 2012, 167, 35-42.	1.9	111
159	Observational Study Mortality in Treated Primary Aldosteronism. Hypertension, 2012, 60, 618-624.	1.3	235
160	Quality of life in patients with primary aldosteronism: Gender differences in untreated and long-term treated patients and associations with treatment and aldosterone. Journal of Psychiatric Research, 2012, 46, 1650-1654.	1.5	47
161	The Adrenal Vein Sampling International Study (AVIS) for Identifying the Major Subtypes of Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 1606-1614.	1.8	310
162	Prevalence, Clinical, and Molecular Correlates of KCNJ5 Mutations in Primary Aldosteronism. Hypertension, 2012, 59, 592-598.	1.3	246

#	Article	IF	Citations
163	Adrenal vein sampling using rapid cortisol assays in primary aldosteronism is useful in centers with low success rates. European Journal of Endocrinology, 2011, 165, 301-306.	1.9	93
164	Automated Chemiluminescence-Immunoassay for Aldosterone during Dynamic Testing: Comparison to Radioimmunoassays with and without Extraction Steps. Clinical Chemistry, 2006, 52, 1749-1755.	1.5	136
165	Dehydroepiandrosterone Supplementation in Healthy Men with an Age-Related Decline of Dehydroepiandrosterone Secretion. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 4686-4692.	1.8	123
166	Neuroendocrine Dysfunction in African Trypanosomiasis: The Role of Cytokinesa. Annals of the New York Academy of Sciences, 1998, 840, 809-821.	1.8	46
167	Expression of adrenocorticotrophic hormone receptor mRNA in human adrenocortical neoplasms: correlation with P450scc expression. Clinical Endocrinology, 1997, 46, 619-626.	1.2	65
168	Thyroid dysfunction in African trypanosomiasis: a possible role for inflammatory cytokines. Clinical Endocrinology, 1993, 39, 455-461.	1.2	21
169	Dehydroepiandrosterone Supplementation in Healthy Men with an Age-Related Decline of Dehydroepiandrosterone Secretion. , 0, .		42